

Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

LRG2.1

RRID:Addgene_108098

Type: Plasmid

Proper Citation

RRID:Addgene_108098

Plasmid Information

URL: <http://www.addgene.org/108098>

Proper Citation: RRID:Addgene_108098

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:29526696](#)

Vector Backbone Description: Backbone Marker:Addgene Plasmid #65656; Backbone Size:9315; Vector Backbone:LRG; Vector Types:Mammalian Expression, Lentiviral, CRISPR; Bacterial Resistance:Ampicillin

Comments: BsmBI digestion for sgRNA cloning

Plasmid Name: LRG2.1

Record Creation Time: 20220422T221524+0000

Record Last Update: 20260725T073438+0000

Ratings and Alerts

No rating or validation information has been found for LRG2.1.

No alerts have been found for LRG2.1.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 47 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Todorov TZ, et al. (2025) Phosphoproteomics Reveals L1CAM-Associated Signaling Networks in High-Grade Serous Ovarian Carcinoma: Implications for Radioresistance and Tumorigenesis. *International journal of molecular sciences*, 26(10).

Lagan E, et al. (2025) A specific form of cPRC1 containing CBX4 is co-opted to mediate oncogenic gene repression in diffuse midline glioma. *Molecular cell*, 85(11), 2110.

Vargas C, et al. (2025) CD44 Marks Dormant Tumor Cells After HER2 Inhibition in Breast Cancer Cells. *International journal of molecular sciences*, 26(10).

Mukhi D, et al. (2025) The actin and microtubule network regulator WHAMM is identified as a key kidney disease risk gene. *Cell reports*, 44(4), 115462.

Liu Q, et al. (2025) In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors. *bioRxiv : the preprint server for biology*.

Ngiow SF, et al. (2024) LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. *Cell*, 187(16), 4336.

He T, et al. (2024) Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies. *Cancer cell*, 42(8), 1336.

Kim IK, et al. (2024) Plasticity-induced repression of *Irf6* underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma. *Nature communications*, 15(1), 1532.

Alpsoy A, et al. (2024) *I?B?* is a dual-use coactivator of NF- κ B and POU transcription factors. *Molecular cell*, 84(6), 1149.

Sreekumar A, et al. (2024) B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling. *Cancer cell*, 42(1), 52.

Thatikonda V, et al. (2024) Genetic dependencies associated with transcription factor activities in human cancer cell lines. *Cell reports*, 43(5), 114175.

Zong D, et al. (2023) Comprehensive mapping of cell fates in microsatellite unstable cancer cells supports dual targeting of WRN and ATR. *Genes & development*, 37(19-20), 913.

Ma C, et al. (2023) A bioengineered immunocompetent human leukemia chip for preclinical screening of CAR T cell immunotherapy. *Research square*.

Chen S, et al. (2023) PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies. *Breast cancer research : BCR*, 25(1), 1.

Sun X, et al. (2023) BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network. *Nature*, 613(7942), 195.

Li F, et al. (2023) Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance. *bioRxiv : the preprint server for biology*.

Gao Y, et al. (2023) ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation. *Nature cell biology*, 25(2), 298.

Kim IK, et al. (2023) Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy. *Research square*.

Zong D, et al. (2023) Comprehensive mapping of cell fates in microsatellite unstable cancer cells support dual targeting of WRN and ATR. *bioRxiv : the preprint server for biology*.

Zhou Y, et al. (2022) EBF1 nuclear repositioning instructs chromatin refolding to promote therapy resistance in T leukemic cells. *Molecular cell*, 82(5), 1003.